Gt biopharma to participate in the h.c. wainwright 24th annual global investment conference in september

Brisbane, calif., sept. 08, 2022 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced that management will present in-person at h.c. wainwright's 24th annual global investment conference taking place september 12-14, 2022 at the lotte new york palace. company management will also be participating in 1x1 meetings during the event.
GTBP Ratings Summary
GTBP Quant Ranking